Clinical trial NCT05653336: PerQseal® Clinical Study
Official title: A Multicentre, Single-Arm, Pivotal Study to Evaluate the Safety and Efficacy of the Vivasure PerQseal® Closure Device System When Used to Achieve Haemostasis of Common Femoral Arteriotomies Created by 12 to 22 F Sheaths in Patients Undergoing Percutaneous Catheter-Based Interventional Procedures
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Percutaneous Large Hole Vascular Closure
Keywords: Vascular Closure
Vascular Closure Device
Large hole percutaneous closure
Large bore percutaneous closure
Lead sponsor: Vivasure Medical Limited
Sponsor class: INDUSTRY
First posted: 2022-12-16
Enrollment: 149
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures.

Detailed description: The objective of this pivotal study is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures, with sufficient rigor to provide robust scientific evidence for the demonstration of clinical safety and efficacy of the PerQseal closure system to support a pre-market approval submission.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 19 years,
2. Clinically indicated for a percutaneous arterial interventional catheter-based procedure, e.g., transcatheter aortic valve replacement/implantation (TAVR/TAVI) or endovascular abdominal aortic aneurysm repair (EVAR), or thoracic endovascular aortic aneurysm repair (TEVAR), or use of a circulatory assist device or extracorporeal oxygenation using a common femoral arteriotomy created by a 12 to 22 F sheath (arteriotomy up to 26 F),
3. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements,
4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.

Baseline Exclusion Criteria:

1. Evidence of current systemic bacterial or cutaneous infection, including groin infection,
2. Known bleeding diathesis, definite or potential coagulopathy, platelet count \< 100,000/µl or subjects on long term anticoagulants with an INR \> 2 within 12 hours prior to index procedure,
3. Significant anaemia (haemoglobin \< 9 g/dL or haematocrit \< 27%), within 24 hours prior to index procedure,
4. Known type II heparin-induced thrombocytopenia,
5. Documented left ventricular ejection fraction \< 20%,
6. Ipsilateral or contralateral lower extremity amputation.
7. Claudication (Rutherford category 3 or greater), documented untreated iliac or common femoral artery diameter stenosis \> 50% or previous bypass surgery/stent placement in the common femoral artery of target leg,
8. Known existing nerve damage in the target leg,
9. Renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine \> 2.5 mg/dL) or on renal replacement therapy,
10. Known allergy to any of the materials used in the PerQseal device (refer to Instructions for Use),
11. Subject unsuitable for surgical repair of the target leg access site,
12. Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90-days prior to index procedure,
13. Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable intravascular closure device for haemostasis, in the target leg, within the 90-days prior to index procedure,
14. Subject has undergone a percutaneous procedure of 8 F sheath or less using a suture mediated closure device or manual/mechanical pressure for haemostasis in the target leg, within the 30-days prior to index procedure,
15. Evidence of marked tortuosity of the femoral or external iliac arteries in the target leg, based on pre-primary procedure CT angiography,
16. Evidence of arterial diameter stenosis \> 30% within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
17. Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
18. Target femoral artery diameter is less than 6 mm or 7 mm, depending on whether S (small) or L (large) PerQseal Introducer will be used for arteriotomy closure, respectively, based on pre-primary procedure CT angiography,
19. Further planned endovascular/catheter-based procedure in the target leg in the 30-days following the index procedure.
20. Subject is enrolled in another investigational medical device or drug study,
21. Subject has been previously enrolled in this clinical study.
22. Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19 within two weeks, or recent exposure to a person with COVID-19 infection within two weeks.

    Procedural Exclusion Criteria:

    If any Procedural Exclusion Criteria listed below are met, then closure with PerQseal device is not permitted.
23. Initial common femoral arterial access achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography).
24. Difficult dilation during initial target femoral artery access (e.g., that damages or kinks dilators) while step-dilating up to the large-bore device,
25. During arterial puncture, the target femoral artery suspected to have experienced a posterior arterial wall needle puncture or underwent \> one needle puncture during the primary procedure (with a needle larger than a Micropuncture needle (\> 21 gauge or \> 0.819 mm diameter) )
26. Subject has a tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than 8 cm.,
27. Significant blood loss requiring transfusion of blood products during primary procedure or within 30-days prior to index procedure,
28. Activated clotting time (ACT) \> 250 seconds immediately prior to sheath removal or if ACT measurements are expected to be \> 250 seconds for more than 24 hours after index procedure,
29. Target puncture site is in a vascular graft,
30. Target arteriotomy greater than 26 F,
31. Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 15 mm proximal of the bifurcation of the superficial femoral/ profunda femoris artery,
32. Target arteriotomy located at the level or above the inferior epigastric artery and/or beneath or above the inguinal ligament based on bony/arterial landmarks (above femoral head on A-P projection),
33. Subjects with an acute haematoma \> 4 cm diameter, arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the target access site identified intra-procedurally,
34. Evidence of bleeding around the primary procedure sheath (VARC type1/BARC type 2 or higher),
35. Intra-procedural angiographic evidence of arterial laceration, dissection or stenosis within the femoral artery that would preclude use of the PerQseal device,
36. Uncontrolled hypertension (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg) at the time of planned vascular closure,
37. Systolic blood pressure \< 90 mmHg at the time of planned vascular closure.

Primary outcomes:
measure: Primary Safety Endpoint - Major Access Site Complications
timeFrame: through 30 days
measure: Primary Effectiveness Endpoint - Time to Hemostasis
timeFrame: 20 Minutes
Secondary outcomes:
measure: Secondary Safety Endpoint - Minor Access Site Complications
timeFrame: through 30 Days
measure: Secondary Effectiveness Endpoint - PerQseal Technical Success Rate
timeFrame: 10 Minutes
measure: Secondary Effectiveness Endpoint - PerQseal Treatment Success Rate
timeFrame: through 30 days
measure: Secondary Effectiveness Endpoint - Time to Device Deployment
timeFrame: 20 Minutes
measure: Secondary Effectiveness Endpoint - Time to Ambulation
timeFrame: through 24 hours
measure: Secondary Effectiveness Endpoint - Total Closure Time
timeFrame: 40 Minutes
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: HonorHealth
state: Arizona
city: La Jolla
country: United States
facility: Scripps
state: California
city: Bangor
country: United States
facility: Northern Light Eastern Maine Medical Center
state: Maine
city: Camden
country: United States
facility: Cooper University Hospital
state: New Jersey
city: Paramus
country: United States
facility: The Valley Hospital
state: New Jersey
city: Bronx
country: United States
facility: Montefiore Medical Center (multiple centers)
state: New York
city: Buffalo
country: United States
facility: University of Buffalo
state: New York
city: New York
country: United States
facility: Columbia University Medical Center/ NewYork Presbyterian Hospital
state: New York
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
city: Stony Brook
country: United States
facility: Stony Brook University Hospital
state: New York
city: Cleveland
country: United States
facility: The Cleveland Clinic
state: Ohio
city: Mechanicsburg
country: United States
facility: UPMC Pinnacle Health
state: Pennsylvania
city: Philadelphia
country: United States
facility: UPenn - Perelman Center for Advanced Medicine,
state: Pennsylvania
city: Wynnewood
country: United States
facility: Lankenau Institute for Medical Research
state: Pennsylvania
city: Houston
country: United States
facility: The Texas Heart Institute
state: Texas
city: Muenster
country: Germany
facility: St Franziskus Hospital
state: North Rhine-Westphalia
city: Leipzig
country: Germany
facility: Leipzig University Hospital
state: Saxony
city: Berlin
country: Germany
facility: St. Gertrauden Krankenhaus (SGK)
Study officials:
affiliation: Lankenau heart Institute
name: William Gray, Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: The Cleveland Clinic
name: Sean Lyden, Dr.
role: PRINCIPAL_INVESTIGATOR
References: